S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:AFMD

Affimed Stock Forecast, Price & News

$6.52
-0.06 (-0.91 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.23
Now: $6.52
$6.59
50-Day Range
$5.62
MA: $6.42
$7.20
52-Week Range
$1.42
Now: $6.52
$7.48
Volume1.54 million shs
Average Volume2.17 million shs
Market Capitalization$575.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Affimed logo

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

341st out of 1,925 stocks

Pharmaceutical Preparations Industry

181st out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2167-4360
Employees137

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.96 million
Book Value$0.57 per share

Profitability

Net Income$-36,250,000.00
Net Margins-172.01%

Miscellaneous

Market Cap$575.89 million
Next Earnings Date4/27/2021 (Estimated)
OptionableOptionable
$6.52
-0.06 (-0.91 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Affimed (NASDAQ:AFMD) Frequently Asked Questions

How has Affimed's stock price been impacted by COVID-19 (Coronavirus)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AFMD stock has increased by 258.2% and is now trading at $6.52.
View which stocks have been most impacted by COVID-19
.

Is Affimed a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Affimed?

Wall Street analysts have given Affimed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Affimed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Affimed's CEO?

1,448 employees have rated Affimed CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Affimed's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Affimed
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) released its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $12.33 million for the quarter, compared to the consensus estimate of $6.34 million. Affimed had a negative net margin of 172.01% and a negative return on equity of 99.24%.
View Affimed's earnings history
.

What price target have analysts set for AFMD?

2 brokerages have issued 1-year target prices for Affimed's shares. Their forecasts range from $9.00 to $10.00. On average, they expect Affimed's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price.
View analysts' price targets for Affimed
or view Wall Street analyst' top-rated stocks.

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 60)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 57)
  • Prof. Melvyn Little, Founder & Consultant
  • Mr. Angus W. Smith, Chief Financial Officer (Age 39)
  • Dr. Arndt J. G. Schottelius, Chief Scientific Officer (Age 55)
  • Mr. Michael Wolf, Head of Fin. & Admin. (Age 54)
  • Mr. Alexander Fudukidis, Head of Investor Relations
  • Dr. Uwe Reusch, Head of Cell Culture
  • Dr. Stefan Knackmuss, Head of Antibody Screening
  • Dr. Sergey Kipriyanov, Head of R&D

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by many different institutional and retail investors. Top institutional investors include Vigilare Wealth Management (0.05%).

Which institutional investors are buying Affimed stock?

AFMD stock was acquired by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $6.52.

How big of a company is Affimed?

Affimed has a market capitalization of $575.89 million and generates $23.96 million in revenue each year. The biopharmaceutical company earns $-36,250,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Affimed employs 137 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.